MedTrace Logo

Asian Registry of the BioFreedom Stent for STEMI Patients

NCT03609346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 914

Last updated 2024-02-29

No results posted yet for this study

Summary

The BioFreedom BA9 (Stainless Steel) Drug Coated Stent is an approved stent that is already commercially available in Europe and Asia. The purpose of this registry is to assess the safety and efficacy of the BioFreedom stent for treatment of a specific group of patients; patients with a myocardial infarction (STEMI). The objective is to capture patients' outcomes and antithrombotic strategies data using one or several BioFreedom Stents in the routine treatment of these STEMI patients.

Conditions

  • STEMI - ST Elevation Myocardial Infarction

Interventions

DEVICE

PCI

The placement of 1 or more stents in the diseased coronary artery lesion(s).

Sponsors & Collaborators

  • Biosensors Interventional Technologies Pte Ltd

    collaborator UNKNOWN

  • Biosensors Europe SA

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2022-01-30
Completion
2022-08-05

Countries

  • Hong Kong
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609346 on ClinicalTrials.gov